Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Chimerix (NASDAQ:CMRX) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $11.00 price target on the biopharmaceutical company’s stock.

CMRX has been the topic of a number of other research reports. StockNews.com downgraded Chimerix from a hold rating to a sell rating in a report on Tuesday. Wedbush restated an outperform rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday.

Chimerix Trading Up 9.5 %

CMRX stock opened at $0.84 on Wednesday. Chimerix has a one year low of $0.75 and a one year high of $1.30. The firm has a market capitalization of $75.65 million, a PE ratio of -0.91 and a beta of 1.20. The firm has a 50-day moving average of $0.88 and a two-hundred day moving average of $0.97.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.23). The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same quarter in the prior year, the company earned ($0.21) EPS. On average, equities research analysts anticipate that Chimerix will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Chimerix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its holdings in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares during the last quarter. Vestal Point Capital LP acquired a new position in Chimerix during the fourth quarter valued at approximately $1,348,000. Pale Fire Capital SE grew its holdings in Chimerix by 113.6% during the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 112,318 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Chimerix in the second quarter valued at approximately $137,000. Finally, Marquette Asset Management LLC boosted its position in shares of Chimerix by 24.3% in the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares during the period. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.